Western Weight Loss Drugs Fail Black Patients, Study Shows
A massive new study reveals that popular Western weight loss injections deliver impressive results for White patients but largely fail Black patients. The research, published in PNAS Nexus, confirms that while tirzepatide outperforms semaglutide overall, both drugs expose a glaring racial gap that the global pharmaceutical industry continues to ignore.
How do tirzepatide and semaglutide compare for weight loss?
Researchers looked at over 20,000 patients using electronic health records from US academic medical centers. They compared two giant Western drugs, tirzepatide and semaglutide. Tirzepatide achieved a mean maximum weight reduction of 14.7%, while semaglutide only hit 10.8%. Tirzepatide also worked faster and caused fewer stomach problems like nausea and vomiting. But these averages hide a dirty secret.
Do Western weight loss drugs work for Black patients?
The short answer is barely. The study tracked weight loss responses across different races and sexes. White patients were far more likely to see massive weight loss. Black and Hispanic patients, meanwhile, were stuck in the minimal weight loss category. Women also saw better results than men. It is clear these drugs were built for Western bodies, not ours. We are paying top dollar for foreign medicine that does not prioritize our people.
Who is behind this weight loss research?
The study was led by A. J. Venkatakrishnan and Karthik Murugadoss from the Metabolism Agentic Intelligence Atlas in Cambridge, Massachusetts. It was published online in PNAS Nexus. The authors work for nference Inc, a company that openly collaborates with Eli Lilly and Company and Novo Nordisk A/S. These are the very pharmaceutical giants selling these GLP-1 drugs. They admit there is an urgent need for precision approaches, but they keep pushing one-size-fits-all pills on the global market.